Skip to main content

Table 2 Description of the seven teicoplanin-related adverse events observed in 6 of the 60 included patients

From: Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration

Case

Modified CCI

BJI type

AE subtype

CTCAE grade

Route

Dosage

Delay

Companion drug

Stop

Hospitalization (duration)

Resolution

1

5

Acute osteomyelitis

Rash maculo-papular

2

IV

12 mg/L

7 days

None

Yes

Yes (3 days)

Yes

2

4

Acute PJI

Rash maculo-papular

2

IV

No

10 days

Oxacillin

Clindamycin

Yes

No (17 days)

Yes

3

0

Acute VO

Rash maculo-papular

Pancytopenia

3

SC

No

11 days

Rifampicin

Yes

No

Yes

4

5

Chronic osteomyelitis

Headache

1

IV

27.8 mg/L

20 days

Rifampicin

Yes

No

Yes

5

2

Chronic VO

Rash maculo-papular

3

SC

No

22 days

Ofloxacin

Yes

Yes (4 days)

Yes

6

2

Acute VO

Rash maculo-papular

2

IV

No

14 days

Ofloxacin

Yes

No

Yes

  1. AE adverse event, BJI bone and joint infection, CCI Charlson’s comorbidity index, CTCAE common terminology criteria for adverse events, IV Intravenous, PJI prosthetic joint infection, SC subcutaneous, VO vertebral osteomyelitis